Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 3 Interventional Results available

Assessment of the Safety and Efficacy Study of RGN-259 Ophthalmic Solutions for Neurotrophic Keratopathy : SEER-1

ClinicalTrials.gov ID: NCT02600429

Public ClinicalTrials.gov record NCT02600429. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 5, 2026, 9:15 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Phase 3, Multi-Center, Randomized, Double Masked, Placebo Controlled Clinical Study to Assess the Safety and Efficacy of RGN-259 Ophthalmic Solution for the Treatment of Neurotrophic Keratopathy: SEER-1

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The objective of this study is to assess the safety and efficacy of RGN-259 Ophthalmic Solution compared to placebo for the treatment of NK.

Study identification

NCT ID
NCT02600429
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 3
Lead sponsor
ReGenTree, LLC
Industry
Enrollment
18 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Sep 16, 2015
Primary completion
Nov 19, 2019
Completion
Mar 8, 2020
Last update posted
Aug 29, 2023

2015 – 2020

United States locations

U.S. sites
11
U.S. states
7
U.S. cities
10
Facility City State ZIP Site status
Hull Eye Center Lancaster California 93534
Vision Institute Colorado Springs Colorado 80907
Eye Center of Northern Colorado Fort Collins Colorado 80525
Insight Vision Group Parker Colorado 80134
Medical Faculty Associates, Inc. Washington D.C. District of Columbia 20037
Midwest Cornea Associates, LLC Indianapolis Indiana 46290
Koffler Vision Group Lexington Kentucky 40509
Richard Eiferman, MD, PSC Louisville Kentucky 40205
The Eye Care Institute Louisville Kentucky 40206
Central Maine Eye Care Lewiston Maine 04240
Black Hills Regional Eye Institute Rapid City South Dakota 57701

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02600429, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Aug 29, 2023 · Synced Sep 5, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02600429 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →